Document:

Exhibit 10.1

 

AMENDMENT NO. 1 TO

 

2011 SECURITIES PURCHASE AGREEMENT

 

This Amendment No. 1 (this “Amendment”),
dated as of January 29, 2014, is by and among Champions Oncology, Inc. (the “Company”), Battery Ventures IX,
L.P. (“Ventures”) and Battery Investment Partners IX, LLC (together with Ventures, “Battery”).

 

WHEREAS, the Company, Battery and
certain other parties are parties to the Securities Purchase Agreement (the “Securities Purchase Agreement”)
dated as of March 24, 2011; and

 

WHEREAS, the Company and Battery
wish to amend certain provisions of the Securities Purchase Agreement;

 

NOW, THEREFORE, in consideration
of the mutual promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and Battery hereby agree as follows.

 

1.         The definition of “Change
of Control” in Section 1.4 of the Securities Purchase Agreement is hereby replaced in its entirety with the following:

 

“Change of Control” means the occurrence
of any one or more of the following events: (i) the sale or other disposition to an unrelated party of all or substantially all
of the assets of the Company, in one transaction or a series of transactions (other than financing arrangements); or (ii) a merger,
consolidation or share exchange involving the Company and any other person or entity (other than for the purposes of reincorporation),
in which the Company or one of its subsidiaries is not the surviving entity, after approval of the Board of Directors.

 

2.         All other provisions of the Securities
Purchase Agreement shall remain intact. This Amendment shall be interpreted in accordance with the governing law and jurisdiction
provisions of Section 7.7 of the Securities Purchase Agreement. This Amendment may be executed in any number of counterparts, each
of which shall be deemed an original, and all of which together shall constitute one and the same instrument. This Amendment may
be executed and delivered by facsimile transmission or email.

 

[Remainder of page intentionally left blank]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Amendment as of the date first written above.

 

	 	CHAMPIONS ONCOLOGY, INC.	 
	 	 	 
	 	 	 	 	 
	 	By:	/s/ Joel Ackerman	 
	 	Name:	Joel Ackerman	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	BATTERY VENTURES IX, L.P.	 
	 	 	 
	 	By:	Battery Partners IX, LLC	 
	 	 	General Partner	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin	 
	 	 	Name:	Scott Tobin	 
	 	 	Title:	Member Manager	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	BATTERY INVESTMENT PARTNERS, IX, LLC	 
	 	 	 
	 	By:	Battery Partners IX, LLC	 
	 	 	Managing Member	 
	 	 	 	 
	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin	 
	 	 	Name:	Scott Tobin	 
	 	 	Title:	Member ManagerExhibit 10.2

 

AMENDMENT NO. 1 TO

 

2013 SECURITIES PURCHASE AGREEMENT

 

This Amendment No. 1 (this “Amendment”),
dated as of January 29, 2014, is by and among Champions Oncology, Inc. (the “Company”), Battery Ventures IX,
L.P. (“Ventures”), Battery Investment Partners IX, LLC (together with Ventures, “Battery”)
and PAR Investment Partners, L.P. (“PAR”).

 

WHEREAS, the Company, Battery, PAR
and certain other parties are parties to the Securities Purchase Agreement (the “Securities Purchase Agreement”)
dated as of January 28, 2013; and

 

WHEREAS, the Company, Battery and
PAR wish to amend certain provisions of the Securities Purchase Agreement;

 

NOW, THEREFORE, in consideration
of the mutual promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each of Battery and PAR hereby agree as follows.

 

1.         The definition of “Change
of Control” in Section 1.3 of the Securities Purchase Agreement is hereby replaced in its entirety with the following:

 

“Change of Control” means the occurrence
of any one or more of the following events: (i) the sale or other disposition to an unrelated party of all or substantially all
of the assets of the Company, in one transaction or a series of transactions (other than financing arrangements); or (ii) a merger,
consolidation or share exchange involving the Company and any other person or entity (other than for the purposes of reincorporation),
in which the Company or one of its subsidiaries is not the surviving entity, after approval of the Board of Directors.

 

2.         All other provisions of the Securities
Purchase Agreement shall remain intact. This Amendment shall be interpreted in accordance with the governing law and jurisdiction
provisions of Section 6.7 of the Securities Purchase Agreement. This Amendment may be executed in any number of counterparts, each
of which shall be deemed an original, and all of which together shall constitute one and the same instrument. This Amendment may
be executed and delivered by facsimile transmission or email.

 

[Remainder of page intentionally left blank]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Amendment as of the date first written above.

 

	 	CHAMPIONS ONCOLOGY, INC.	 
	 	 	 
	 	 	 	 	 	 
	 	By:	/s/ Joel Ackerman	 
	 		Name: Joel Ackerman	 
	 		Title:   Chief Executive Officer	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	BATTERY VENTURES IX, L.P.	 
	 	 	 
	 	By:	Battery Partners IX, LLC	 
	 	 	General Partner	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin	 
	 	 		Name: Scott Tobin	 
	 	 		Title:   Member Manager	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	BATTERY INVESTMENT PARTNERS, IX, LLC	 
	 	 	 
	 	By:	Battery Partners IX, LLC	 
	 	 	Managing Member	 
	 	 	 	 
	 	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin	 
	 	 		Name: Scott Tobin	 
	 	 		 	Title:   Member Manager	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	PAR INVESTMENT PARTNERS, L.P.	 
	 	 	 
	 	By:	PAR Group, L.P.	 
	 	 	General Partner	 
	 	 	 	 
	 	 	By:	PAR Capital Management, Inc.	 
	 	 	 	General Partner	 
	 	 	 	 	 	 
	 	 	 	By:	Steven  Smith	 
	 	 	 	 	Name:Steven M. Smith	 
	 	 	 	 	Title:Chief Operating OfficerExhibit 10.3

 

PUT RIGHT AGREEMENT

 

This Put Right Agreement (this “Agreement”),
by and among Champions Oncology, Inc. (the “Company”), Joel Ackerman (“Ackerman”) and Ronnie
Morris (“Morris”), is dated effective as of January 29, 2014.

 

WHEREAS, the Company, Ackerman, Morris
and certain other persons and entities are party to a Securities Purchase Agreement dated as of March 24, 2011 (the “2011
Securities Purchase Agreement”) and a Securities Purchase Agreement dated as of January 28, 2013 (together with the 2011
Securities Purchase Agreement, the “Securities Purchase Agreements”), pursuant to which Ackerman, Morris and
the other persons and entities purchased shares of common stock from the Company and, in some cases, received warrants to purchase
additional shares;

 

WHEREAS, the Securities Purchase
Agreements both provide for the ability of the investors, under certain circumstances, to put their shares to the Company for the
original purchase price in the event of a Put Option Trigger Event (as defined in each of the Securities Purchase Agreements);

 

WHEREAS, Ackerman and Morris are
each a member of the Company’s Board of Directors;

 

WHEREAS, the Company and each of
Ackerman and Morris want to clarify their roles both as potential beneficiaries of the Put Rights (as defined in each of the Securities
Purchase Agreements) and members of the Company’s Board of Directors;

 

NOW, THEREFORE, in consideration
of the mutual promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each of Ackerman and Morris hereby agree as follows.

 

1.        Each of Ackerman and Morris hereby
agree that, if the Company’s Board of Directors is voting on a transaction, event or approval that would constitute a Put
Option Trigger Event, each of Ackerman and Morris shall either (a) recuse themselves from voting as a member of the Board of Directors
on such transaction, event or approval or (b) be entitled to vote but forego exercising or receiving the benefit of their Put Right
(as defined in each of the Securities Purchase Agreements).

 

2.        All other provisions of the Securities
Purchase Agreements shall remain intact. This Agreement shall be interpreted in accordance with the governing law and jurisdiction
provisions of the Securities Purchase Agreements. This Agreement may be executed in any number of counterparts, each of which shall
be deemed an original, and all of which together shall constitute one and the same instrument. This Agreement may be executed and
delivered by facsimile transmission or email.

 

[Remainder of page intentionally left blank]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.

  

	 	CHAMPIONS ONCOLOGY, INC.	 
	 	 	 
	 	 	 	 
	 	By:	/s/ David Sidransky	 
	 		Name: David Sidransky	 
	 		Title:   Chairman of the Board of Directors	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	/s/ Joel Ackerman	 
	 	 	Joel Ackerman	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	/s/ Ronnie Morris	 
	 	 	 Ronnie MorrisSeptember 23, 2013

  
 

  
I, Joseph Riccelli, am lending Innovative Designs, Inc the amount of $55,000 Dollars, for a period of 180 days, at an interest rate of 10%. Repayment of $60,500, interest included will be made by March 23, 2014.

  
 

  	
  
/s/ Joseph Riccelli

	
  
 

	
  
Joseph Riccelli

	
  
 

	
  
 

	
  
 

	
  
/s/ Gregory P. Domian 

	
  
 

	
  
Gregory P. Domian - WitnessAugust 10, 2013

  
 

  
Xunjin Hua is lending Innovative Designs, Inc the amount of $25,000 Dollars, for a period of 6 months, at an interest rate of 10% for six months. Repayment of $27,500 interest included will be made by February 10, 2014. In addition, lender will receive 5,000 shares of IVDN stock as additional interest.

  
 

  	
  
/s/ Xunjin Hua

	
  
 

	
  
Xunjin Hua

	
  
 

	
  
 

	
  
 

	
  
/s/ Joseph Riccelli

	
  
 

	
  
Joseph Riccelli

	
  
 

	
  
 

	
  
 

	
  
/s/ Gregory P. Domian

	
  
 

	
  
(Witness)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]